Get the Stockscreener App
6.11
0.00%
0.00
Ardelyx Inc stock is traded at $6.11, with a volume of 3.62M.
It is up +0.00% in the last 24 hours and up +38.08% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$6.11
Open:
$6.08
24h Volume:
3.62M
Relative Volume:
0.80
Market Cap:
$1.47B
Revenue:
$386.15M
Net Income/Loss:
$-56.39M
P/E Ratio:
-26.57
EPS:
-0.23
Net Cash Flow:
$-55.19M
1W Performance:
+2.35%
1M Performance:
+38.08%
6M Performance:
+20.75%
1Y Performance:
+0.99%
1-Day Range:
$6.08
$6.29
1-Week Range:
$5.7809
$6.29
52-Week Range:
$3.21
$7.18
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
6.11 | 1.40B | 386.15M | -56.39M | -55.19M | -0.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
How Ardelyx Inc. stock performs during market volatility2025 AllTime Highs & Safe Capital Growth Trade Ideas - Newser
Multi asset correlation models including Ardelyx Inc.Gap Down & Verified Stock Trade Ideas - Newser
Analyzing net buyer seller activity in Ardelyx Inc.Portfolio Value Report & Technical Confirmation Trade Alerts - Newser
Applying chart zones and confluence areas to Ardelyx Inc.Fed Meeting & Daily Market Momentum Tracking - Newser
Volume spikes in Ardelyx Inc. stock – what they mean2025 Institutional Moves & Real-Time Volume Analysis - Newser
Ardelyx, Inc. (NASDAQ:ARDX) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Live market analysis of Ardelyx Inc.July 2025 Update & Fast Gain Swing Alerts - Newser
Will Ardelyx Inc. benefit from macro trendsWeekly Trade Recap & High Conviction Investment Ideas - Newser
Why Ardelyx (ARDX) Is Up 10.6% After Raising IBSRELA Sales Outlook and Reporting Strong Q2 Revenue - simplywall.st
Can you recover from losses in Ardelyx Inc.Rate Cut & Reliable Intraday Trade Alerts - Newser
What candlestick patterns are forming on Ardelyx Inc.Weekly Stock Analysis & AI Based Trade Execution Alerts - Newser
Ardelyx Inc. stock trend outlook and recovery pathMarket Volume Summary & Smart Investment Allocation Insights - Newser
Statistical indicators supporting Ardelyx Inc.’s strengthEarnings Trend Report & Trade Opportunity Analysis Reports - Newser
Why Ardelyx Inc. is moving todayPortfolio Growth Summary & Advanced Swing Trade Entry Alerts - Newser
Will Ardelyx Inc. outperform the marketMarket Activity Report & AI Forecast for Swing Trade Picks - Newser
Automated trading signals detected on Ardelyx Inc.Weekly Gains Report & Weekly Setup with High ROI Potential - Newser
What makes Ardelyx Inc. stock price move sharply2025 Analyst Calls & Growth Focused Entry Reports - Newser
Tools to assess Ardelyx Inc.’s risk profileMarket Performance Summary & Weekly Breakout Stock Alerts - Newser
Visual trend scoring systems applied to Ardelyx Inc.July 2025 Weekly Recap & Low Risk High Reward Trade Ideas - Newser
Ardelyx (ARDX) Appoints New Chief Business and HR Officers - MSN
Ardelyx Inc. Breaks Below Key Support LevelMarket Activity Report & Daily Technical Forecast Reports - 선데이타임즈
Pattern Scan Adds Ardelyx Inc. to WatchlistJuly 2025 Catalysts & High Accuracy Buy Signal Tips - sundaytimes.kr
Ardelyx's Accelerating Revenue Growth and Strategic Momentum in 2025: A Deep Dive into IBSRELA's Surge and XPHOZAH's Resilience - AInvest
Ardelyx: Improved Outlook For Ibsrela And Xphozah (NASDAQ:ARDX) - Seeking Alpha
Ardelyx (ARDX) Is Up 10.6% After Raising 2025 IBSRELA Sales Guidance and Posting Strong Q2 Results - simplywall.st
Blair William & Co. IL Boosts Stake in Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Ardelyx Inc. Flashes Rebound Signal in Oversold Condition2025 Earnings Surprises & Community Consensus Stock Picks - beatles.ru
Ardelyx Inc. stock trend outlook and recovery path [Earnings Growth Summary]Fast Exit Strategy with Risk Control - Newser
Is Ardelyx Inc. exposed to currency risksFree Stock Market Entry Signals - thegnnews.com
Ardelyx (ARDX) Is Up 20.3% After Raising IBSRELA Sales Guidance and Announcing Leadership ChangesWhat's Changed - simplywall.st
Ardelyx Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Can Ardelyx’s (ARDX) Leadership Changes and Raised Guidance Reshape Its Long-Term Growth Prospects? - simplywall.st
Piper Sandler Maintains a Hold Rating on Ardelyx (ARDX) - MSN
Little Excitement Around Ardelyx, Inc.'s (NASDAQ:ARDX) Revenues As Shares Take 26% Pounding - 富途牛牛
Ardelyx Q2 Revenue Jumps 33% - AOL.com
Understanding Ardelyx Inc.’s price movementSmart Entry Signals for Active Traders - Newser
Ardelyx raises 2025 IBSRELA revenue guidance to $250M–$260M amid sustained demand growth - MSN
Ardelyx Inc. Faces Financial Uncertainty Amid Shifting Trade Policies - The Globe and Mail
Ardelyx Inc. Q2 2025 Earnings Call Highlights - The Globe and Mail
Ardelyx price target raised to $9 from $8 at Piper Sandler - TipRanks
Insiders Of Ardelyx Are Up 20% On Their US$6.78m Purchase - 富途牛牛
Ardelyx, Inc. (NASDAQ:ARDX) Q2 2025 Earnings Call Transcript - Insider Monkey
Ardelyx Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Ardelyx Inc Faces Uncertainty Amid Shifting Trade Policies - AInvest
BTIG Remains a Buy on Ardelyx (ARDX) With a $14 PT - MSN
Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming - MSN
Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming By Stocktwits - Investing.com India
Ardelyx Surpasses Expectations with Remarkable Q2 Performance - timothysykes.com
Ardelyx Stock Soars: Time to Buy? - StocksToTrade
Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating - MarketScreener
Ardelyx shares rise 13.21% premarket after reporting strong Q2 revenue growth and raising 2025 sales expectations. - AInvest
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ardelyx Inc Stock (ARDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOTT DAVID M | Director |
Jun 09 '25 |
Buy |
3.69 |
200,000 |
737,260 |
2,696,871 |
| Williams Laura A | Chief Medical Officer |
May 20 '25 |
Sale |
4.08 |
6,421 |
26,207 |
402,583 |
| Renz Justin A | Chief Financial Officer |
May 20 '25 |
Sale |
4.08 |
7,218 |
29,460 |
416,089 |
| RAAB MICHAEL | President & CEO |
May 20 '25 |
Sale |
4.08 |
46,817 |
191,079 |
1,547,937 |
| Kelliher Mike | See Remarks |
May 20 '25 |
Sale |
4.08 |
14,522 |
59,270 |
282,158 |
| GRAMMER ELIZABETH A | See Remarks |
May 20 '25 |
Sale |
4.08 |
5,992 |
24,456 |
311,731 |
| Foster Eric Duane | Chief Commercial Officer |
May 20 '25 |
Sale |
4.08 |
2,507 |
10,232 |
316,806 |
| MOTT DAVID M | Director |
May 15 '25 |
Buy |
3.29 |
100,000 |
329,120 |
2,496,871 |
| MOTT DAVID M | Director |
May 02 '25 |
Buy |
4.22 |
381,377 |
1,610,936 |
2,396,871 |
| RAAB MICHAEL | President & CEO |
May 02 '25 |
Option Exercise |
0.99 |
20,833 |
20,625 |
1,636,420 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):